| Name | Title | Contact Details |
|---|
Notal Vision was founded in 2000 by ophthalmologists and medical device professionals determined to reduce vision loss associated with age-related macular degeration (AMD). With leading experts in the field, this team of medical professionals and scientists developed a new, patented technology for monitoring AMD. This new technology, Preferential Hyperacuity Perimetry, is now providing eye care professionals around the world with valuable clinical data for monitoring patients with AMD.
Open System Mri is a Palm Desert, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
dermpath diagnostics is a Palm Beach Gardens, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aurora Diagnostics is a leading independent pathology services and cancer diagnostics company, offering integrated diagnostic and personalized medicine consultations and information technology solutions to physicians and hospital systems. Our pathologists provide diagnostic opinions and work collaboratively with referring physicians to determine appropriate patient treatment options. We also provide services to pharmaceutical companies and other research entities to support their efforts to develop new cancer treatments. Our client-centric approach to providing diagnostic services is driven by our belief that the practice of medicine and the delivery of healthcare are both personal and best delivered locally. With our extensive pathology expertise, Aurora Diagnostics is able to support comprehensive integrated approaches to patient care.
Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals. We have brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy. With our unique approach to immuno-oncology, we are developing next-generation personalized immunotherapies to fight cancer in patients with the most difficult-to-treat tumors. We plan to combine these personalized neoantigen-targeted therapies with current immune checkpoint modulatory approaches to improve response rates and survival in patients with solid tumors.